Abstract
4512 Background: Although genotype-phenotype correlations have been described for different subtypes of renal cell carcinoma (RCC), it is unknown if DNA methylation profiles correlate with morphological or ontology based phenotypes. Here we test the hypothesis that DNA methylation signatures of different RCC can discriminate between putative precursor cells in the nephron. Methods: We performed deep profiling of DNA methylation using Digital Restriction Analysis of DNA Methylation (DREAM) based on next generation sequencing analysis of methylation-specific signatures in diverse histopathological RCC subtypes (n = 22). We furthermore validated our findings in an independent dataset of diverse histopathological RCC subtypes (n = 44) and in The Cancer Genome Atlas Clear Cell (n = 424) and Chromophobe Renal Cell Carcinoma (n = 66) Datasets. Results: Our data provide the first mapping of methylome epi-signature and indicates that RCC subtypes can be grouped into two major epi-clusters: C1 which encompasses clear-cell RCC (n = 4), papillary RCC (n = 5), mucinous and spindle cell carcinomas (n = 2) and translocation RCC (n = 5); C2 which comprises oncocytoma (n = 2) and chromophobe RCC (n = 4). Interestingly, C1 epi-cluster displayed three fold more hypermethylation as compared to C2 epi-cluster. Of note, differentially methylated regions between C1 and C2 epi-clusters occur in gene bodies and intergenic regions, instead of gene promoters. These data was validated in an independent dataset using supervised clustering. Transcriptome analysis of C1 epi-cluster suggests a functional convergence on Polycomb targets, whereas C2 epi-cluster displays DNA methylation defects. Finally, our epigenetic ontogeny signature was associated with worse outcomes of patients with clear-cell RCC, suggesting that cell of origins matters for RCC prediction purposes. Conclusions: Our data defines two epi-clusters that can discriminate between distinct RCC subtypes and for the first time, to our knowledge, define the epigenetic basis for proximal versus distal tubule derived kidney tumors. Genes defining ontogeny epi-signature might be used in the future to predict patients outcome.